Products for Research Use Only

Ethamsylate

CAT: 0804-HY-B1074-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1074-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis.[1][2][3].
CAS Number
2624-44-4
Product Name Alternative
Etamsylate
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Ethamsylate.html
Purity
99.49
Solubility
DMSO : 120 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
Smiles
O=S(C1=CC(O)=CC=C1O)(O)=O.CCNCC
Molecular Formula
C10H17NO5S
Molecular Weight
263.31
Precautions
H302, H315, H319, H335
References & Citations
[1]Zawrotniak M, et al. Selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (NETs) . Acta Biochim Pol. 2015;62 (3) :465-73.|[2]Kovács L, et al. Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. Experientia. 1981 Nov 15;37 (11) :1182-3.|[3]Albiñana V, et al. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition) . TH Open. 2019 Jul 26;3 (3) :e230-e243. |[4]Dolma S, et al. Ethamsylate Attenuates Mutilated Secondary Pathogenesis and Exhibits a Neuroprotective Role in Experimental Model of Spinal Cord Injury. Neuroscience. 2022 Feb 21;484:26-37.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched